InvestorsHub Logo
Followers 33
Posts 2837
Boards Moderated 2
Alias Born 10/24/2015

Re: NY1972 post# 192

Thursday, 11/17/2022 6:31:03 PM

Thursday, November 17, 2022 6:31:03 PM

Post# of 391
Most are going that route, including them. When the S-1 was filed (the IPO has now been abandoned), said they would be using CRISPR (electroporation wasn't going to be used) to knockout genes that encode inhibitory receptors, and could knockout/in genes to improve persistence, with them hinting at B2M/CIITA KO and HLA-E KI. But no additional details, such as editing efficacy were presented.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News